Anaptysbio, Inc financial data

Symbol
ANAB on Nasdaq
Industry
Pharmaceutical Preparations
Location
10770 Wateridge Circle, Suite 210, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
ANAPTYS BIOSCIENCES INC (to 11/20/2007)
Latest financial report
10-K - Q4 2024 - Feb 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1K % -9.94%
Return On Equity -273 % -128%
Return On Assets -32.1 % +1.54%
Operating Margin -126 % +86.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 30.7M shares +14.6%
Common Stock, Shares, Outstanding 30.5M shares +14.6%
Entity Public Float 488M USD +33.1%
Common Stock, Value, Issued 30K USD +11.1%
Weighted Average Number of Shares Outstanding, Basic 28.4M shares +5.42%
Weighted Average Number of Shares Outstanding, Diluted 28.4M shares +5.42%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 91.3M USD +432%
Research and Development Expense 42.2M USD +36.7%
General and Administrative Expense 42.4M USD +1.06%
Operating Income (Loss) -115M USD +30.1%
Nonoperating Income (Expense) -30.3M USD -3943%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -32.9M USD +11.9%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -145M USD +11.2%
Earnings Per Share, Basic -5.12 USD/shares +15.8%
Earnings Per Share, Diluted -5.12 USD/shares +15.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 123M USD +242%
Assets, Current 432M USD +6.16%
Property, Plant and Equipment, Net 1.85M USD -11.9%
Operating Lease, Right-of-Use Asset 14.4M USD -11.1%
Other Assets, Noncurrent 256K USD 0%
Assets 484M USD +6.95%
Accounts Payable, Current 4M USD -14.8%
Employee-related Liabilities, Current 8.45M USD +17.3%
Accrued Liabilities, Current 39.5M USD +27.6%
Liabilities, Current 45.4M USD +21.3%
Operating Lease, Liability, Noncurrent 14.1M USD -12%
Accumulated Other Comprehensive Income (Loss), Net of Tax 305K USD
Retained Earnings (Accumulated Deficit) -759M USD -23.7%
Stockholders' Equity Attributable to Parent 70.9M USD -19.6%
Liabilities and Equity 484M USD +6.95%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -37.3M USD -51.6%
Net Cash Provided by (Used in) Financing Activities -13.6M USD +63.7%
Net Cash Provided by (Used in) Investing Activities 68.6M USD -19.7%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 30.5M shares +14.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 17.7M USD -23.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 123M USD +242%
Deferred Tax Assets, Valuation Allowance 187M USD +23.7%
Deferred Tax Assets, Gross 194M USD +22.7%
Operating Lease, Liability 16M USD -9.98%
Payments to Acquire Property, Plant, and Equipment 27K USD -84.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -144M USD +9.45%
Lessee, Operating Lease, Liability, to be Paid 18.4M USD -11.8%
Property, Plant and Equipment, Gross 8.45M USD +1.59%
Operating Lease, Liability, Current 1.93M USD +8.33%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.61M USD +3%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.53M USD +3.01%
Operating Lease, Weighted Average Discount Rate, Percent 0.04 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2.34M USD -22.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.69M USD +2.99%
Deferred Tax Assets, Operating Loss Carryforwards 70.7M USD -2.82%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 6.91M USD +37.8%
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.77M USD +3.02%
Operating Lease, Payments 602K USD +2.91%
Additional Paid in Capital 830M USD +18.1%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 163K USD -1.81%
Share-based Payment Arrangement, Expense 34M USD +2.54%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%